Investigational drug · Phase 2
ACT001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent Glioblastoma Multiforme(GBM).
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "ACT001"
First trial start
2021
Sep 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACT001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Glioblastoma Multiforme(GBM)
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ACT001" as an intervention, largest first.
- ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasRecruiting
Nationwide Children's HospitalAcademic, hospital or other
NCT06838676 · 60 participants (planned) · Start Jul 10, 2025 · Primary completion Jul 2028
Drug: ACT001 · For: Diffuse Intrinsic Pontine Gliomas (DIPG); Progressive DIPG; Refractory DIPG and 2 more
Sites: Aurora, Colorado; Washington D.C., District of Columbia; Miami, Florida · 20 sites in all
- A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeActive, not recruiting
Accendatech USA Inc.Industry
NCT05053880 · 48 participants (planned) · Start Sep 22, 2021 · Primary completion Oct 25, 2024
Drug: ACT001; ACT001 + Pembrolizumab · For: Recurrent Glioblastoma Multiforme(GBM)
Sites: Houston, Texas
- Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple MyelomaNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT06594211 · 18 participants (planned) · Start Oct 9, 2024 · Primary completion Oct 9, 2028
Drug: ACT-001 CAR-NK cell · For: Multiple Myeloma
Sites: Shanghai, China
- A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate CancerEnrolling by invitation
Zhejiang UniversityAcademic, hospital or other
NCT07240857 · 18 participants (planned) · Start Apr 12, 2026 · Primary completion Oct 31, 2026
Drug: Intraprostatic or localized lesion injection of ACT#001-PSMA CAR-T cells under transrectal ultrasound (TRUS) guidance · For: Castration-Resistant Prostate Cancer (CRPC)
Sites: Hangzhou, China
National Neuroscience InstituteAcademic, hospital or other
NCT06894225 · 12 participants (planned) · Start Mar 22, 2025 · Primary completion May 2027
Drug: ACT001 · For: Recurrent Glioblastoma
Sites: Singapore, Singapore
Newest research
PubMed records naming it or its code names, newest first.
- Mass balance and metabolite profiles in humans of ACT001, a novel sesquiterpene lactone derivative, using 14C-radiolabelled techniques.
Yuan J, Zhang H, Bian Y, et al. · Br J Clin Pharmacol 2026
- Targeting MD2 in diseases: from structure and function to inhibitor development.
Cheng F, Yang F, Xiao S, et al. · Eur J Med Chem 2026
- Conformational switching and spatial heterogeneity: Decoding SERPINE1/PAI-1as a multifaceted driver of tumor progression and therapy resistance.
Guo X, Xia S, Wang K, et al. · Crit Rev Oncol Hematol 2026
- Targeting the "Undruggable" STAT3 DBD: Free-Energy Perturbation-Guided Design of Covalent Micheliolide Derivatives Targeting Cysteine 367.
Deng Y, Bian H, Zhang F, et al. · J Chem Inf Model 2026
- ACT001 suppresses ox-LDL-mediated macrophage ferroptosis via activating the NRF2 pathway: An in vitro mechanistic study relevant to atherosclerosis.
Tao Y, Chen Y, Zhao Y, et al. · Exp Ther Med 2026
- Micheliolide and ACT001 as Covalent Modulators of Inflammation-Redox-Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges.
Jing D, Chu H · Drug Des Devel Ther 2026
Also in development for Recurrent Glioblastoma Multiforme(GBM)
- JL15003InjectionPhase 21 trial
Jecho Biopharmaceuticals Co., Ltd. · Recurrent Glioblastoma Multiforme(GBM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.